Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
▼
$0.02
$80K1.5923.72 million shsN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$441K0.11251,859 shs13,898 shs
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
$0.16
+0.1%		$0.22
$0.16
▼
$0.90
$278K0.412,706 shs500 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+70.88%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%0.00%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+166.67%+60.00%-20.00%-82.22%
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
0.00%-8.18%-30.00%-39.96%-81.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
▼
$0.02
$80K1.5923.72 million shsN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$441K0.11251,859 shs13,898 shs
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
$0.16
+0.1%		$0.22
$0.16
▼
$0.90
$278K0.412,706 shs500 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+70.88%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%0.00%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%+166.67%+60.00%-20.00%-82.22%
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
0.00%-8.18%-30.00%-39.96%-81.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.01N/AN/AN/A∞
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
$1.05M0.26N/AN/A($6.77) per share-0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A11/6/2026 (Estimated)
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
-$10.37M-$3.49N/AN/AN/A-682.67%N/A-261.90%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
N/A
0.47
0.30

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
Invitae Co. stock logo
NVTA
Invitae
61.28%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
24.22%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
Invitae Co. stock logo
NVTA
Invitae
0.74%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
29.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
61.14 million1.10 millionNo Data
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionNo Data
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
949551.28 million536.95 millionNo Data
Longevity Health Holdings, Inc. stock logo
XAGE
Longevity Health
101.78 million1.27 millionN/A

Recent News About These Companies

Longevity Health Holdings Enters into Securities Purchase Agreement for Up to $625,000 in Gross Proceeds
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357565/0/en/longevity-health-holdings-enters-into-securities-purchase-agreement-for-up-to-625-000-in-gross-proceeds.html
Longevity Health Raises Capital via Secured Convertible Note
September 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/longevity-health-raises-capital-via-secured-convertible-note?utm_source=marketbeat.com&utm_medium=referral
Longevity Health Holdings Announces Settlement of Litigation with Puritan Partners LLC
August 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346173/0/en/longevity-health-holdings-announces-settlement-of-litigation-with-puritan-partners-llc.html
Longevity Health Announces Routine Board Member Resignation
June 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/longevity-health-announces-routine-board-member-resignation?utm_source=marketbeat.com&utm_medium=referral
Head to Head Contrast: Longevity Health (NASDAQ:XAGE) & Biosig Technologies (NASDAQ:STEX)
March 27, 2026  |  defenseworld.netD
Longevity Health Holdings Closes Strategic Investment and Appoints Ram Ajjarapu as Chairman and CEO to Drive Acquisition-Focused Growth
March 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/17/3257196/0/en/longevity-health-holdings-closes-strategic-investment-and-appoints-ram-ajjarapu-as-chairman-and-ceo-to-drive-acquisition-focused-growth.html
Longevity Health Holdings Ends Merger with True Health
December 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/longevity-health-holdings-ends-merger-with-true-health?utm_source=marketbeat.com&utm_medium=referral
Why Longevity Health Stock Is Skyrocketing Today
July 15, 2025  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/25/07/46430331/why-longevity-health-stock-is-skyrocketing-today
Why Longevity Health Stock Is Skyrocketing Today
July 15, 2025  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/25/07/46430331/why-longevity-health-stock-is-skyrocketing-today?utm_source=snapi
Why did XAGE Stock Surge in Today’s Premarket Trading?
July 15, 2025  |  tokenist.comT
Longevity Health Holdings, Inc.: Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction
July 15, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-07/65907064-longevity-health-holdings-inc-longevity-health-holdings-announces-merger-with-thplasma-and-termination-of-20-20-biolabs-transaction-399.htm
Longevity Health Holdings to Merge With True Health
July 15, 2025  |  marketwatch.comhttps://www.marketwatch.com/story/longevity-health-holdings-to-merge-with-true-health-5632aee0
Longevity Health stock soars after merger with THPlasma in all-stock deal
July 15, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/longevity-health-stock-soars-after-merger-with-thplasma-in-allstock-deal-93CH-4135554
Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction
July 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/14/3115204/0/en/Longevity-Health-Holdings-Announces-Merger-with-THPlasma-and-Termination-of-20-20-BioLabs-Transaction.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 09/25/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0008 0.00 (0.00%)
As of 09/25/2026 03:41 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Longevity Health stock logo

Longevity Health NASDAQ:XAGE

$0.16 +0.00 (+0.06%)
As of 09/25/2026 02:41 PM Eastern

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas